Strategic MOU combines Neo-Pharma’s biopharmaceutical R&D capabilities with VIRTUALMAN’s AI-powered molecular design platform to advance next-generation therapeutics.
SINGAPORE — October 5, 2026 — Neo Pharma Biotech Pte. Ltd. (“Neo-Pharma”) today announced the signing of a Memorandum of Understanding (MOU) with ChemAI Co., Ltd. (operating under the brand VIRTUALMAN). The strategic partnership unites Neo-Pharma’s expertise in target selection, medicinal chemistry, and translational R&D with VIRTUALMAN’s cutting-edge computational drug discovery and AI-driven molecular design platform to explore new frontiers in drug candidate optimization and global commercialization.
This collaboration marks a significant milestone in Neo-Pharma’s strategy to leverage innovative technologies to improve drug discovery efficiency. By combining AI computational workflows with practical drug development capabilities, both companies aim to enhance lead compound screening, optimize molecular profiles, improve early-stage decision-making, and accelerate promising therapeutic candidates from research into pipeline development.
High-Efficiency AI Drug Discovery & Development Framework
Under the MOU framework, Neo-Pharma and VIRTUALMAN will initially prioritize joint evaluations across several key areas:
- AI-Driven Discovery & Lead Optimization: Applying computational tools for molecular design, hit-to-lead identification, candidate optimization, and druggability property profiling.
- Early Predictive & Feasibility Profiling: Conducting early-stage predictive analysis covering physicochemical properties, ADMET/PK profiles, toxicity risks, formulation feasibility, and synthetic accessibility.
- Project-Based Feasibility Studies: Executing targeted pilot studies and Proof-of-Concept (PoC) assessments on selected drug programs to evaluate technical synergy, data requirements, and development potential.
- Co-Development Opportunities: Evaluating high-potential therapeutic programs and assets for prospective joint research and co-development.
- International Business Development: Partnering on global market expansion, industrial collaboration, licensing negotiations, and commercialization initiatives.
Strengthening Neo-Pharma’s AI-Enabled Pipeline
Neo-Pharma has built a strong foundation in innovative small molecule discovery, maintaining an end-to-end value chain spanning early research, candidate optimization, preclinical development, and international licensing.
Integrating VIRTUALMAN’s AI and computational capabilities into Neo-Pharma’s workflow empowers research teams to evaluate and refine candidates with greater precision and data-driven confidence. Rather than replacing traditional drug discovery, Neo-Pharma views AI as a vital bridge connecting molecular design, medicinal chemistry, wet-lab validation, and translational development—establishing a scalable, highly efficient AI-enabled drug development engine.
Bridging Technical R&D to Global Markets
Beyond R&D, both organizations will explore commercial models suited for international markets, including joint development, technology licensing, and global commercialization strategies. Neo-Pharma continues to integrate biopharmaceutical resources across Asia and global markets to strengthen its global competitiveness and advance innovative therapies toward clinical development.
Neo-Pharma stated:
“Artificial intelligence is rapidly reshaping the landscape of drug discovery, but its true value is unlocked when AI technology seamlessly integrates with deep drug development experience. This partnership with VIRTUALMAN bridges cutting-edge AI molecular design with Neo-Pharma’s strengths in medicinal chemistry, translational research, and commercial execution. By leveraging our complementary strengths, we look forward to accelerating the evaluation and translation of innovative therapeutics and exploring broader international opportunities.”
VIRTUALMAN will contribute its computational drug discovery, molecular design, and AI-driven optimization capabilities to collaboratively evaluate target research and development projects with Neo-Pharma.
About Neo Pharma Biotech Pte. Ltd.
Neo Pharma Biotech Pte. Ltd. (Neo-Pharma) is a biopharmaceutical company headquartered in Singapore, dedicated to the discovery and development of innovative small molecule therapeutics. Neo-Pharma focuses on building a comprehensive value chain from early target selection through preclinical development to global licensing and commercialization.
About ChemAI Co., Ltd. (VIRTUALMAN)
ChemAI Co., Ltd., operating under the brand VIRTUALMAN, is an AI-driven drug discovery company focused on small-molecule lead optimization and preclinical property prediction. VIRTUALMAN integrates molecular design, property prediction, ADMET assessment, synthetic feasibility analysis, and customized modeling to support candidate optimization and early-stage drug development decisions, with a particular focus on advancing promising new drug programs and revitalizing existing drug assets.